Inhibition breast carcinogenesis via PI3K/AKT pathway using bioactive compounds of Strychnine tree (Strychnos nux-vomica): in silico study
DOI:
https://doi.org/10.12928/pharmaciana.v14i2.28242Keywords:
PI3K/AKT pathway, AKT1, strychnine tree compounds, target analysis, molecular docking, molecular dynamicsAbstract
Breast cancer poses a significant global health challenge, with a notable prevalence in Indonesia. Given the intricate nature of breast cancer progression and classification, precise treatment strategies are imperative, particularly targeting signaling pathways like PI3K/AKT, pivotal in cell growth, proliferation, survival, and apoptosis. Bioactive compounds from the Strychnine tree demonstrate potential in enhancing apoptotic effects and inhibiting breast carcinogenesis. This potential is explored through in silico studies. This research aims to analyze potential targets of Strychnine tree compounds, along with binding energy and stability between ligands and receptors. Employing bioinformatics target analysis, molecular docking, and molecular dynamics simulation, the study reveals AKT1 as a potential target of Strychnine tree compounds. These compounds inhibit AKT1 at both active and allosteric sites, displaying notably low binding energy scores. For example, brucine exhibits a binding energy of -10.83 kJ/mol at the active site, surpassing the standard capivasertib. However, lupeol, with a binding energy of -11.14 kJ/mol, falls short of the MK-2206 standard at the allosteric site. Molecular dynamics simulations expose fluctuations in parameters like RMSD, RMSF, and binding energy within the initial 5 ns. In conclusion, Strychnine tree compounds, such as brucine and lupeol, showcase potential AKT1 inhibition at both active and allosteric sites, enhancing apoptotic effects. However, the stability of these compounds in binding to their receptors within the first 5 ns of the simulation warrants further investigation for prolonged interactions.
Downloads
Published
Issue
Section
License
Authors who publish with Pharmaciana agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.